Here is a summary of today's most impactful Wall Street research rating changes, which are closely watched and can influence market movements, for investors' reference.
**Five Notable Rating Upgrades**
Goldman Sachs upgraded
**Five Notable Rating Downgrades**
Stephens & Co. downgraded The Cheesecake Factory (CAKE) from Overweight to Equal Weight, maintaining a $65 price target. The company's fourth-quarter same-store sales declined by 2.2%, indicating a sequential slowdown in growth. Cantor Fitzgerald downgraded Polestar (PSNY) from Neutral to Underweight and did not provide a price target. Reasons included lowered delivery expectations, additional financing needs, recent stock price appreciation, and an unclear autonomous driving strategy. Roth Capital downgraded Fiverr (FVRR) from Buy to Neutral, slashing its price target from $32 to $14. This followed the company's quarterly results missing expectations and a downward revision to its outlook, with Citigroup and JPMorgan also downgrading the stock to Neutral-equivalent ratings. Scotiabank downgraded HF Sinclair (DINO) from Sector Outperform to Sector Perform, lowering its price target from $62 to $53. The downgrade reflects significant uncertainty due to the CEO's leave of absence and an Audit Committee review of disclosure processes. D. Boral Capital downgraded GeoVax Labs (GOVX) from Buy to Hold and did not provide a price target. The firm cited the company's limited near-term prospects, a lack of significant catalysts, and tightening financial conditions.
**Five Notable Initiations of Coverage**
Benchmark initiated coverage on Lear (LEA) with a Buy rating and a $170 price target, believing the company stands to benefit from trends in vehicle electrification and premium interior content. Mizuho Securities initiated coverage on Tempus AI (TEM) with an Outperform rating and a $100 price target, citing the large and fast-growing market for precision oncology diagnostics. RBC Capital Markets initiated coverage on Rhythm Pharmaceuticals (RYTM) with an Outperform rating and a $478 price target, highlighting the company's innovative therapies in the rare genetic obesity space. Goldman Sachs initiated coverage on Credo Technology (CRDO) with a Buy rating and a $165 price target, projecting approximately 27% upside potential. Canaccord Genuity initiated coverage on Kiniksa Pharmaceuticals (KNSA) with a Buy rating and a $62 price target, noting that its drug Arcalyst is the only FDA-approved treatment for recurrent pericarditis.